Random Dermatology MCQ - Type III dysbetalipoproteinemia
A 55-year-old fisherman presents with asymptomatic, waxy, yellow-orange papules coalescing into plaques on his neck and axillae. The lesions appear stuck-on and show a positive folded ear sign.
RANDOM DERMATOLOGY MCQS
9/23/20251 min read
A 55-year-old fisherman presents with asymptomatic, waxy, yellow-orange papules coalescing into plaques on his neck and axillae. The lesions appear stuck-on and show a positive folded ear sign. A skin biopsy reveals dermal deposition of lipid-laden macrophages. Which of the following is the most likely underlying metabolic abnormality?
A) Type I hyperlipoproteinemia
B) Type IIa hypercholesterolemia
C) Type III dysbetalipoproteinemia
D) Type IV hypertriglyceridemia
E) Type V mixed hyperlipidemia
Correct Answer: C) Type III dysbetalipoproteinemia
Explanation
Key Features of Eruptive Xanthomas in Type III Dysbetalipoproteinemia:
Clinical Presentation:
Tuberoeruptive xanthomas: Yellow-orange papules/plaques on extensor surfaces (elbows, knees) and intertriginous areas.
"Folded ear" sign: Xanthomatous infiltration of the anthelix (pathognomonic for type III).
Palmar xanthomas: Orange-yellow streaks in palmar creases.
Histopathology:
Foamy macrophages in the dermis with lipid deposition.
Perivascular inflammation may be present.
Metabolic Defect:
Defective ApoE2 clearance of chylomicron/VLDL remnants → elevated IDL.
Lab findings: ↑↑ cholesterol + triglycerides, "broad beta band" on lipoprotein electrophoresis.
Why Not Other Options?
(A) Type I: Eruptive xanthomas (trunk/buttocks) + lipemia retinalis (LPL deficiency).
(B) Type IIa: Tendon xanthomas (Achilles/extensors), normal triglycerides.
(D) Type IV: Eruptive xanthomas (high TG only), no folded ear sign.
(E) Type V: Mixed eruptive + tuberous xanthomas, no palmar involvement.
Management:
First-line: Fibrates (gemfibrozil) to reduce IDL.
Statin adjunct: If LDL remains elevated.
Dietary: Low-fat, reduced alcohol.
Prognosis: High risk for premature atherosclerosis if untreated.
© 2025. All rights reserved.